Overview
Switzerland delivery device maker's FY revenue declined 4.8% organically
Adjusted EBITDA margin improved to 20%, driven by higher Dental volumes and efficiency gains
Net income rose to CHF 7.0 mln from a loss in the previous year
Outlook
Medmix expects 2026 organic revenue growth to be flat to low single digits
Company forecasts 2026 adjusted EBITDA margin around 20%
Medmix increases mid-term adjusted EBITDA margin guidance to above 21%
Result Drivers
BEAUTY DEMAND - Revenue in the Beauty segment fell 12.9% due to weak end markets and project delays
DUAL SOURCING IMPACT - Drug Delivery revenue dropped 19.6% due to customer dual sourcing and non-repeat project milestones
EFFICIENCY GAINS - Improved margins attributed to cost savings and efficiency gains from Growth & Efficiency program
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Miss
CHF 448 mln
CHF 453.65 mln (2 Analysts)
FY Adjusted EBITDA
CHF 89.70 mln
FY Adjusted EBITDA Margin
20.00%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for medmix AG is CHF18.00, about 58.2% above its February 25 closing price of CHF11.38
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)